Ritalin (methylphenidate) is a central nervous system stimulant that causes an increase in mental alertness by increasing the amount and effectiveness of a neurotransmitter in the body called dopamine. It is a prescription-only medication in the United States. Ritalin is primarily used to treat attention-deficit hyperactivity (ADHD) and is also used in the treatment of narcolepsy.

Dosage FAQs

Drug Interactions of Ritalin

If your doctor prescribes you this medication, be sure to discuss all minerals, vitamins, medications, and supplements you regularly take. The following drugs may interact with Ritalin:

Adverse Effects of Ritalin

This medication is associated with several serious and some less serious side effects. Some of the adverse effects of Ritalin include:

Precautions Associated with Ritalin

Ritalin is contraindicated for those experiencing glaucoma, motor tics, and Tourette syndrome. Additionally, it should not be taken if the person requiring treatment has used an MAOI drug within the past two weeks.

If you are undergoing prolonged therapy with this medication, discuss periodic blood tests with your physician. Many sources recommend periodic complete blood counts (CBC), blood differential tests, and platelet counts to ensure there is not too much buildup of this medication in your system.

Ritalin should be used with extreme caution by those experiencing high blood pressure.

Safe Withdrawal from Ritalin

If you need to stop taking this medication, it is best to consult with your doctor to work out a safe plan for withdrawal. It is possible to build both tolerance and a dependency on Ritalin. To reduce the occurrence and severity of withdrawal symptoms, dosage should be tapered down over time if possible. It may take anywhere from a few days to a few weeks for Ritalin to completely clear from your system. If you stop taking this drug abruptly, you may experience varying degrees of:

References:

  1. Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, Chyka PA, Booze LL, Manoguerra AS, Nelson LS, Christianson G, Troutman WG (2007). "Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology 45 (7): 737–52. doi:10.1080/15563650701665175. PMID 18058301.
  2. Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs 20 (9): 713–38. doi:10.2165/00023210-200620090-00002. PMID 16953648.
  3. Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (1983). "Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid". Pediatrics 72 (1): 56–59. PMID 6866592.
  4. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006). "Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size". Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent 15 (1): 27–39. PMC 2277275. PMID 18392193.

Page content reviewed by James Pendleton, ND.